{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T18:27:15Z","timestamp":1776709635877,"version":"3.51.2"},"reference-count":75,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,1,4]],"date-time":"2006-01-04T00:00:00Z","timestamp":1136332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The activity of thalidomide in relapsed or refractory multiple myeloma is widely accepted but not yet demonstrated in a randomised\u2010controlled trial. A systematic review of the published clinical trials of these patients could reduce the possible bias of single phase\u2010II studies. A systematic search identified 42 communications reporting on 1674 patients. Thirty\u2010two trials used an escalating dosing regimen and four a fixed dose regimen (one dose with 50\u2003mg\/d, three doses with 200\u2003mg\/d). The target dose in the dose escalating trials was 800\u2003mg\/d in 17 trials, 400\u2013600\u2003mg\/d in 10 and 200\u2003mg\/d in one trial. The intention\u2010to\u2010treat population for efficacy was 1629 patients with a median age of 62\u2003years. The complete and partial (&gt;50% reduction in monoclonal protein) response rate was 29\u00b74% (95%\u2010confidence interval, 27\u201332%). The rates for minor responses or stable disease were 13\u00b78% (12\u201316%) and 11\u00b70% (9\u201313%). Progressive disease was reported in 9\u00b79% (8\u201311%). The median overall survival from all trials was reported at 14\u2003months. Severe adverse events (grade III\u2013IV) included somnolence 11%, constipation 16%, neuropathy 6%, rash 3%, thrombo\u2010embolism 3%, cardiac 2%. In conclusion, thalidomide monotherapy achieved complete and partial responses in 29\u00b74% of patients with relapsed or refractory multiple myeloma.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2005.05914.x","type":"journal-article","created":{"date-parts":[[2006,1,18]],"date-time":"2006-01-18T12:14:34Z","timestamp":1137586474000},"page":"584-593","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":193,"title":["A systematic review of phase\u2010II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma"],"prefix":"10.1111","volume":"132","author":[{"given":"Axel","family":"Glasmacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinna","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"von Lilienfeld\u2010Toal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katjana","family":"Orlopp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Schmidt\u2010Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Gorschl\u00fcter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,1,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197208)30:2<382::AID-CNCR2820300213>3.0.CO;2-C"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(00)90079-9"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2003.09.006"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04345.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198405243102104"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.2.492"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90017-4"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1045"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011141009812"},{"issue":"1","key":"e_1_2_6_11_1","first-page":"S233","article-title":"Thalidomide treatment of patients with advanced multiple myeloma","volume":"4","author":"Bila J.","year":"2003","journal-title":"Hematology Journal"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"e_1_2_6_13_1","first-page":"524","article-title":"Thalidomide with or without dexamethasone for refractory multiple myeloma","volume":"57","author":"Boulin M.","year":"2002","journal-title":"Therapie"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.03902.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1674"},{"issue":"1","key":"e_1_2_6_16_1","first-page":"308b","article-title":"Low\u2010dose thalidomide in patients with advanced, refractory multiple myeloma","volume":"94","author":"Chen C.I.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_17_1","first-page":"278a","article-title":"Thalidomide in relapsed multiple myeloma patients and changes in circulating TNF\u2010alpha, IL\u20106, bFGF and VEGF","volume":"21","author":"Del Vecchio M.","year":"2002","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011132808904"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.200"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200326"},{"key":"e_1_2_6_21_1","first-page":"1","article-title":"Efficacy of low dose thalidomide in multiple myeloma","volume":"1","author":"Durie B.G.M.","year":"2000","journal-title":"Electronic Journal of Oncology"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000087037"},{"key":"e_1_2_6_23_1","volume-title":"Empfehlungen zur Anwendung von Thalidomid bei Patienten mit einem multiplen Myelom","author":"Glasmacher A.","year":"2005"},{"key":"e_1_2_6_24_1","first-page":"S234","article-title":"ThaCyDex in relapsed\/refractory multiple myeloma","volume":"4","author":"Gonzalez\u2010Porras J.R.","year":"2003","journal-title":"Hematology Journal"},{"key":"e_1_2_6_25_1","first-page":"163a","article-title":"Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM). A prospective study of 120 patients","volume":"98","author":"Grosbois B.","year":"2001","journal-title":"Blood"},{"key":"e_1_2_6_26_1","first-page":"383b","article-title":"Thalidomide at very low dosage may represent an effective therapy in relapsed and refractory multiple myeloma","volume":"102","author":"Guglielmelli T.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)01292-0"},{"key":"e_1_2_6_28_1","first-page":"378b","article-title":"Long term survival and complete remission of chemotherapy refractory multiple myeloma with thalidomide","volume":"100","author":"Helgason H.H.","year":"2002","journal-title":"Blood"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0700-7"},{"key":"e_1_2_6_30_1","first-page":"404","article-title":"Thalidomide treatment of resistant or relapsed multiple myeloma patients","volume":"86","author":"Hus M.","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_6_31_1","first-page":"S235","article-title":"Doxil, Vincristine, Decadron and Thalidomide (DVd\u2010T) for relapsed\/refractory multiple myeloma (RMM)","volume":"4","author":"Hussein M.A.","year":"2003","journal-title":"Hematology Journal"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290006143"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01983.x"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2002.tb02480.x"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000123492"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01835.x"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04473.x"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.34"},{"key":"e_1_2_6_39_1","first-page":"227","article-title":"[Preliminary results of monotherapy with thalidomide in recurrent and treatment resistant cases of multiple myeloma]","volume":"56","author":"Kyrcz\u2010Krzemien S.","year":"2003","journal-title":"Wiadomosci Lekarskie"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1527"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2846"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3846"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03576_4.x"},{"key":"e_1_2_6_44_1","first-page":"3377","article-title":"Dose\u2010dependent effect of thalidomide on overall survival in relapsed multiple myeloma","volume":"8","author":"Neben K.","year":"2002","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"e_1_2_6_45_1","first-page":"40","article-title":"Response to thalidomide can be predicted by paraprotein quantitation 14\u2003days after initiating therapy","volume":"113","author":"Oakervee H.E.","year":"2001","journal-title":"British Journal of Haematology"},{"issue":"1","key":"e_1_2_6_46_1","first-page":"S230","article-title":"Combination therapy with thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma","volume":"4","author":"Offidani M.","year":"2003","journal-title":"Hematology Journal"},{"key":"e_1_2_6_47_1","first-page":"368","article-title":"Single\u2010agent thalidomide for advanced and refractory multiple myeloma","volume":"44","author":"Okikawa Y.","year":"2003","journal-title":"Rinsho Ketsueki. Japanese Journal of Clinical Hematology"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442516"},{"key":"e_1_2_6_49_1","first-page":"399","article-title":"Low\u2010dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma","volume":"86","author":"Palumbo A.","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_6_50_1","first-page":"S233","article-title":"Low\u2010dose thalidomide and dexamethasone improves survival in multiple myeloma patients. (Abstract)","volume":"4","author":"Palumbo A.","year":"2003","journal-title":"Hematology Journal"},{"key":"e_1_2_6_51_1","first-page":"597","article-title":"Thalidomide before autologous stem cell transplantation in VAD\u2010refractory multiple myeloma patients","volume":"88","author":"Patriarca F.","year":"2003","journal-title":"Haematologica"},{"issue":"1","key":"e_1_2_6_52_1","first-page":"227","article-title":"Thalidomide (Thal) an active agent for multiple myeloma (MM) does not chenge the prognosis of plasma cell leukemia (PCL) patients. Experience of a single center","volume":"4","author":"Petrucci M.T.","year":"2003","journal-title":"Hematology Journal"},{"key":"e_1_2_6_53_1","first-page":"1111","article-title":"Low\u2010dose of thalidomide in the treatment of refractory myeloma","volume":"85","author":"Pini M.","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.4065\/75.9.897"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.116"},{"issue":"1","key":"e_1_2_6_56_1","first-page":"168a","article-title":"Durable response to thalidomide in relapsed\/refractory multiple myeloma (MM)","volume":"96","author":"Raza S.N.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.875"},{"key":"e_1_2_6_58_1","first-page":"832","article-title":"Extramedullary multiple myeloma escapes the effect of thalidomide","volume":"89","author":"Rosinol L.","year":"2004","journal-title":"Haematologica"},{"issue":"1","key":"e_1_2_6_59_1","first-page":"228","article-title":"Thalidomide in relapsed and refractory multiple myeloma: a retrospective analysis of efficacy and toxicity","volume":"4","author":"Schauvliege L.","year":"2003","journal-title":"Hematology Journal"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(03)00027-4"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"e_1_2_6_62_1","first-page":"408","article-title":"Salvage therapy with thalidomide in patients with advanced relapsed\/refractory multiple myeloma","volume":"87","author":"Tosi P.","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_6_63_1","volume-title":"Guidelines on the Diagnosis and Management of Multiple Myeloma 2005","author":"UK Myeloma Forum & The Nordic Myeloma Study Group","year":"2005"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04879.x"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327480301000504"},{"issue":"1","key":"e_1_2_6_66_1","first-page":"604a","article-title":"Thalidomide alone or with dexamethasone for multiple myeloma","volume":"94","author":"Weber D.M.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.139"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000067918"},{"key":"e_1_2_6_69_1","first-page":"1445","article-title":"Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%","volume":"146","author":"Wu K.L.","year":"2002","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200175"},{"issue":"2","key":"e_1_2_6_71_1","first-page":"456b","article-title":"Thalidomide (Thal) as salvage therapy for relapsed multiple myeloma (MM) after allogeneic stem cell transplantation (SCT)","volume":"102","author":"Yakoub\u2010Agha I.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1614"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0335"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-40965"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05078.x"},{"key":"e_1_2_6_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh026"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2005.05914.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2005.05914.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T22:05:30Z","timestamp":1697407530000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2005.05914.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,26]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1111\/j.1365-2141.2005.05914.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05914.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,26]]},"assertion":[{"value":"2006-01-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}